A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients (vol 147, pg 259, 2020)-MedSci.cn

A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients (vol 147, pg 259, 2020)

Wang, ZJ; Zhao, J; Ma, ZY; Cui, JW; Shu, YQ; Liu, Z; Cheng, Y; Leaw, SJ; Wu, YJ; Ma, Y; Tan, W; Ma, XP; Zhang, Y; Wang, J

Wang, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr,Dept Med Oncol,State Key Lab Mol On, 17 Pan Jia Yuan South Lane, Beijing 100021, Peoples R China.

LUNG CANCER, 2021; 158 (): 166

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients (vol 147, pg 259, 2020)

科室

工具

服务